Actively Recruiting
Novel Medical Device for Pharmacological Therapy
Led by Fundacion Miguel Servet · Updated on 2025-04-22
262
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: Different co-creation methods were used to design and prototype a new fixative device for multiple intravenous therapies with the ability to control and identify the pharmacological therapy administered to a patient. Objectives: To validate a newly created device for the reduction of complications related to the use of intravenous therapy Methods: A multidisciplinary team composed of eight professionals specializing in the field of critical care and an engineering professional in industrial design was responsible for collecting, evaluating, and materializing the ideas and needs arising from clinical practice in a device that met the standards of the same.
CONDITIONS
Official Title
Novel Medical Device for Pharmacological Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to the intensive care unit
- Patients with authorization to take part in the study
You will not qualify if you...
- Patients with diseases affecting coagulation, such as hemophilia or thrombocytopathies
- Patients with active vascular access site infections or systemic infections
- Patients unable to understand or provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Universitario de Navarra
Pamplona, Navarre, Spain, 31005
Actively Recruiting
Research Team
M
marta M FERRAZ-TORRES, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here